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W. A. SEED 
Department of Medicine, Charing Cross and Westminster Medical School, St Dunstan’s Road, 
London, U.K. 
Lung function was measured at 3-month intervals for up to 1 yr in a group of Caucasian HIV- 
seropositive subjects. The objective was to document any deterioration in lung function and seek 
correlations between such deterioration and smoking history and Centers for Disease Control (CDC) 
status. Ninety-nine subjects were studied at enrolment; 43 were followed-up (mean duration 9 f 3 
months). Ninety-five of the 99 enrolled subjects remained free of HIV-related respiratory disease and 
were included in the analysis. 
At enrolment, carbon monoxide diffusing capacity (RCQ) was significantly lower than predicted in 
non-smokers, smokers and ex-smokers (88, 77 and 88%, respectively, P<O.OOl). The RCO measure- 
ments in the smoking group were significantly lower than those of the life-long non-smoking subjects 
(P<O.Ol). Residual volume (RV) was significantly higher than predicted in smokers (ill%, P=O.O2). 
During follow-up, all three groups demonstrated significant declines in TLC0 (7%, P=O.Ol; 9%, 
P=O.O05; 13%, P<O.OOl, respectively), and increases in RV (9%, P=O.O3; 13.5%, P=O.O2; 22%, PzO.02, 
respectively). 
At enrolment, significantly lower than predicted values of RCO were observed in groups stratified by 
CDC criteria: in asymptomatic HIV-seropositive subjects (CDC II) 89%, P=O.Ol; persistent generalized 
lymphadenopathy (PGL) 84%; AIDS-related complex (ARC) 81%; and in non-pulmonary AIDS (IV Cl) 
69%, P= 0.0001: respectively. Residual volume was significantly higher than predicted in CDC II (114%, 
P=O.O5). During follow-up, RCO fell in groups PGL and ARC by 7 and 9%, respectively, while RV 
increased in groups CDC II, PGL and ARC by 17, 15 and 8%, respectively. Only the TLCO decline in 
PGL showed any linkage to clinical deterioration. 
This study demonstrates deficits at enrolment, and a continuing decline of TLCO and increase in RV 
in HIV-seropositve subjects without overt lung disease. 
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Introduction 
Several studies of lung function in human 
immunodeficiency (HIV) infection have shown a 
reduction of carbon monoxide transfer factor in 
a proportion of HIV-seropositive subjects (l-5). 
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The best documented cause of this reduction 
is Pneumocystis carinii pneumonia (PCP) (4,6), 
but other suggested causes include Kaposi’s 
sarcoma, non-specific interstitial pneumonitis 
(1,3,6) and mycobacterial disease (5). However, 
transfer factor is also reduced in HIV- 
seropositive subjects without overt lung disease 
(3-S) where the cause is unknown. Follow-up 
studies have not identified any cause, but have 
suggested that impairment may be progressive, 
even in asymptomatic subjects. Its severity may 
correlate with the clinical status of the disease as 
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TABLE 1. Demographic and clinical data of total group (n=95) 
(a) By smoking history 
T4 
Age Haemoglobin lymphocyte count 
Group n (years) Pack-year W-‘1 (mm - 3, 
Non-smoker 28 39 0 13 216 
Smoker 51 38 21-f 13.1 334 
Ex-smoker 16 40 10 13 200” 
Mean 39 i 8.2 13 Et 1.9 270 i 180 
*Significantly lower than smokers, P~0.05. 
tsignificantly higher than ex-smokers, P~O.005. 
(b) By CDC group (~~94; one subject unclassifiable) 
CDC Age Haemoglobin 
group n (years) Pack-year W-‘1 
T4 
lymphocyte count 
(mm - 3, 
II 17 35 14 13.9 412 
PGL 25 38 9 13.5 344 
ARC 39 40 14 13* 237” 
IVD 6 41 5” 11.6 781- 
IVC 1 7 42 22 11” 125* 
*Significantly lower than CDC Group II, PcO.05. 
tsignificantly higher than CDC Group II, P<O 005. 
measured by Centers for Disease Control (CDC) 
criteria (4). 
Methods Study Design 
SUBJECTS 
Ninety-nine HIV-seropositive Caucasian sub- 
jects volunteered for the study following direct 
invitation of all eligible patients attending the 
Genito-urinary Medicine departments of two 
large teaching hospitals in West London, U.K. 
(Charing Cross and St Stephen’s Hospitals). 
None of the subjects had a history of intra- 
venous drug abuse; one subject admitted to 
occasional use of recreational drugs. All but 
three (one female) were homosexual. The smok- 
ing histories and clinical status (9) are given in 
Table l(a,b). Four of the subjects developed 
PCP during the study, and were followed-up but 
not included in the analysis. Informed written 
consent was obtained from each subject and 
Subjects were invited to attend at 3-month inter- 
vals. Subjects were instructed to refrain from 
smoking, not to exercise vigorously, and to wear 
comfortable clothing on the day of their tests. At 
enrolment and at subsequent visits, subjects 
underwent an exercise test. On each attendance, 
subjects underwent lung function testing and 
answered a modified Medical Research Council 
respiratory health questionnaire (giving details 
of past medical history, smoking history 
and HIV history including complications and 
therapy). A chest radiograph was taken and 
CD4 counts and haematological indices were 
measured. Subjects were classified as smokers if 
they had smoked at least one cigarette day - i for 
at least 1 yr, and as ex-smokers if they had 
the study was approved by the local Ethics 
Committee. 
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stopped smoking 6 months or more before enrol- 
ment into the study. Smoking was quantified in 
terms of pack-years (packs of 20 smoked day - i 
multiplied by years smoked). None of the smok- 
ing subjects reported a change in their smoking 
habits during the study period. 
Intercurrent episodes of respiratory illness 
were dealt with by outpatient or inpatient ser- 
vices as appropriate. Investigations included 
microbiology, virology, a search for Pneumo- 
cystis by immunofluorescence of samples 
obtained either by sputum induction or bron- 
choscopy, and histological examination of 
transbronchial biopsies. 
Subject Grouping 
Forty-three subjects (45%) were unable to attend 
for follow-up visits due to work or personal 
commitments; 18 subjects (19%) attended twice 
only and 34 subjects (36%) attended three or 
more times. As not all subjects attended for the 
duration of the study, they were divided into 
three groups for analysis on the basis of duration 
of attendance. 
GROUP 1 (n=95) 
This group comprised all subjects who enrolled 
and remained free of respiratory disease. There 
were 28 non-smokers, 51 smokers and 16 
ex-smokers. Of these subjects, 17 were in CDC 
Group II (asymptomatic HIV seropositive); 25 
were in CDC Group III [persistent generalized 
lymphadenopathy (PGL)]; 39 subjects were in 
CDC Group IV [AIDS-related complex (ARC)]; 
and 13 subjects had non-pulmonary AIDS [six 
with Kaposi’s sarcoma (KS); and seven with 
non-pulmonary opportunistic infections)]. The 
authors were unable to obtain CDC data for one 
patient. 
GROUP 2 (n=52) 
A subgroup of Group 1 attended for obser- 
vations on two or more occasions. The group 
comprised 26 smokers, 19 non-smokers and 
seven ex-smokers. Of these subjects, nine were in 
CDC Group II, 16 were in CDC Group III 
(PGL), 20 subjects were in CDC Group IV 
(ARC), and seven subjects had non-pulmonary 
AIDS. Mean length of follow-up was 
9 months f 3 months. 
GROUP 3 (n= 16) 
A small proportion of the total group were able 
to attend for a period of 1 yr or more. From this 
data, rates of change in lung function variables 
could be analysed. This group comprised nine 
smokers and seven non-smokers. 
Pulmonary Function ~ea§~re~e~t~ 
All pulmonary function tests were performed 
seated following a rest period using auto- 
mated equipment (Autolink, P. K. Morgan, 
Gillingham, Kent, U.K.). The equipment was 
calibrated before each subject using standard 
gases. To reduce the risk of cross-infection 
between subjects, disposable Pall Pro-tee Barrier 
filters (Pall Biomedical Products Corp, East 
Hills, New York, U.S.A.) were placed distal to 
the mouthpiece for each test. On a weekly basis, 
equipment dead space (DS) was measured 
(including tubing DS, mouthpiece and Barrier 
filter DS). The P. K. Morgan software package 
(Wyvem) then incorporated the DS into the lung 
function calculations. Vital capacity (VC) and 
forced expiratory volume in 1 s (FEV,) were 
measured by spirometry, lung volumes were 
measured by steady-state helium dilution, and 
carbon monoxide diffusing capacity (TACO) was 
measured by single-breath technique using a test 
gas mixture of 0.3% carbon monoxide, 10% 
helium and 21% oxygen. Subjects inspired at a 
steady rate from residual volume to 90% of 
inspiratory vital capacity. The effective breath 
hold time (10 s) was computed from the time 
when the subject had inspired to 33% of inspired 
volume to the time when 50% of the sample 
volume had been exhaled, The sample volume 
was 900 ml and was collected after voiding the 
first 900 ml of expired gas so as to exclude DS of 
the mouthpiece, filter and upper airway. The 
transfer coefficient (&CO) was obtained by 
dividing TLC0 by alveolar volume (VA), which 
was obtained with each measurement. 
At each visit, all lung function tests were 
performed in duplicate so as to obtain two 
reproducible measurements within 5% of each 
other. In the case of TACO, a mean of two 
224 R. N. MCCABE ET AL. 
reproducible measurements was obtained, and 
was then corrected to a haemoglobin level of 
15.5 g dl- i (10). Predicted values for all lung 
function variables were derived from regression 
equations recently developed in the authors’ 
department from a cohort of normal, non- 
smoking, Caucasian subjects (11). 
Statistical Analysis 
The data were analysed by means of paired or 
unpaired Student’s t-tests and analysis of vari- 
ance (ANOVA) using the computer statistical 
package SPSS (Statistical Package of the Social 
Sciences). A P value of co.05 was accepted as 
significant. Figures show means and standard 
errors of the mean. 
Results 
GROUP 1 
Measurements at Ewolrnent 
Table 1 shows demographic and clinical data of 
all subjects at enrolment, categorized according 
to smoking and CDC status. 
Five subjects changed clinical category during 
the study (one subject changed from CDC II to 
PGL; two subjects changed from PGL to ARC; 
one subject changed from PGL to IVC 1, and 
one subject changed from ARC to IVD). 
In the following tables, lung volume data is 
only presented for variables which showed a 
significant change in one or more groups. 
Additionally, since changes in KC0 followed 
changes in TLC0 in all groups but did not 
always reach significance, only ~?LCO data are 
presented. 
Effects of Smoking [Table 2(a)] 
The smoking group had a significantly higher 
than predicted functional residual capacity 
(FRC) and RV; these values were also signifi- 
cantly higher than those in the non-smoking 
group. Carbon monoxide diffusing capacity and 
KC0 were significantly lower than predicted in 
all three sub-groups. Smokers demonstrated 
a significantly lower TLC0 and KC0 than 
non-smokers. 
Effects of Clinical Status [Table l(b)] 
Carbon monoxide diffusing capacity and KC0 
were significantly lower than predicted values in 
all CDC groups, except in Group IVD (non- 
pulmonary Kaposi’s sarcoma). Residual volume 
was higher than predicted in CDC Group II. 
GROUP 2 
Changes in Lung Function in Relation to Smoking 
[Table 3(a)] 
The mean length of follow-up for the group was 
9 f 3 months, and did not differ between sub- 
groups. All sub-groups showed a significant rise 
in RV and fall in TACO. The smoking group 
showed a significant decrease in KC0 and FVC; 
the ex-smokers showed a significant fall in FEV, 
and FVC. 
Changes in lung Function in Relation to Clinical Status 
[Table 3(b)] 
Spirometric measurements remained unchanged 
in all groups except ARC, where subjects dem- 
onstrated a significant decline in FEV, and FVC. 
The three subjects in the IVC 1 group showed an 
improvement in their small airway function 
(FEFSO). Residual volume increased signifi- 
cantly in groups CDC II, PGL and ARC. 
Carbon monoxide diffusing capacity was signifi- 
cantly impaired in the ARC and PGL groups. In 
order to assess the influence of clinical deterio- 
ration on these results, the five subjects who 
changed clinical category during the period of 
the study were excluded and the data were 
re-analysed. All changes remained statistically 
significant with the exception of TLC0 in the 
PGL group, which appeared to be influenced by 
clinical deterioration. 
GROUP 3 
Pattern of Change over 1 yv (Figs I and 2) 
Data from nine smokers and seven non-smokers 
who attended over a period of 1 yr were analysed 
separately. Mean percent predicted TLC0 
declined progressively in smokers and non- 
smokers; there were no significant differences 
between rates of decline. Percent predicted RV 
increased in both smokers and non-smokers, this 
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TABLE 2(a). Lung function measurements at enrolment compared to predicted values: 
Group 1 subjects categorized by smoking history 
FRC RV TLC0 
ABS PR % ABS PR % ABS PR % 
Non-smoker (n = 28) 3.40 3.50 97 1.73 1.77 98 9.70 11.0 88 
a NS NS P<O.OOl 
Smoker (n = 5 1) 3.89 3.59 108 2.00 1.80 111 8.58 11.2 77 
it 
P=O.O07 P=O.O2 P<O.OOl 
P=O.Ol P=O.O4 PCO.01 
Ex-smoker (n= 16) 3.32 3.42 97 1.80 1.76 102 9.46 10.7 88 
t 
NS NS WO.001 
NS NS NS 
FRC, function residual capacity (1); RV, residual volume (1); TLCO, carbon monoxide 
diffusing capacity (mmol min - ’ kPa- ‘); ABS, absolute; PR, predicted; NS, not significant. 
Row (a), significance of differences between absolute and predicted values. 
Row (b), significance of differences between smokers & non-smokers and ex-smokers & 
non-smokers. 
TABLE 2(b). Lung function measurements at enrolment compared to predicted values: By 
CDC group 
RV TLC0 
ABS PR % ABS PR % 
II (n= 17) 1.85 1.62 114 10.21 11.43 89 
P:L (n=25) 
P=O.O5 P=O.Ol 
1.83 1.75 105 9.21 10.99 84 
ARC (n=39) 
NS P=o~ooo1 
1.95 1.84 106 8.80 10.93 81 
IV; (n=6) 
NS P=o~ooo1 
1.81 1.71 106 9~21 10.53 87 
I& 1 (n=7) 
NS NS 
1.98 2.05 97 7.88 11.38 69 
a NS P=o~ooo1 
RV, residual volume (1); TLCO, carbon monoxide diffusing capacity (mmol min- ’ kPa- ‘); 
ABS, absolute; PR, predicted; NS, not significant. 
Row (a), significance of differences between absolute and predicted values. 
being statistically significant at 9 and 12 months 
in smokers and at 9 months in non-smokers 
(Fig. 2). There were no significant changes in 
TLC in association with the observed increases 
in RV. 
Discussion 
The aim of the present study was to assess the 
influence of smoking and of clinical status on 
lung function over a period of I yr in a group of 
subjects with HIV infection. In particular, the 
authors examined lung volumes as well as 
spirometric and gas transfer measurements. 
Lung volumes measured by helium dilution in 
HIV-seropositive subjects have been studied to a 
lesser extent than gas transfer. The present study 
demonstrated that RV was high at enrolment in 
at least some groups, and increased significantly 
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TABLE 3(a). Lung function measurements at enrolment and on last visit in subjects who 
attended two or more times (n=52): (a) Subjects categorized by smoking history 
First 
RV TLC0 
Last % First Last % 
Non-smoker (n= 19) 
a 
Smoker (n = 26) 
a 
Ex-smoker (n=7) 
a 
1.66 1.81 9 10.02 9.30 7 
P=O.O3 P=O.Ol 
1.92 2.18 13.5 9.21 8.41 9 
P=O.O02 P=O.O05 
1.84 2.25 22 9.89 8.64 13 
P=O.O2 P=O.OOl 
RV, residual volume (1); TXO, carbon monoxide diffusing capacity (mmol min - ’ kPa - ‘). 
Row (a), significance of differences between first and last values, ‘%’ column showing 
percent change during study. 
TABLE 3(b). Lung function measurements at enrolment and on last visit in subjects who 
attended two or more times (n=52): (b) Subjects categorized by CDC grouping 
First 
RV 
Last % First 
TLC0 
Last % 
II (n=9) 
F’:L (n= 16) 
AIL (n=20) 
a 
IVD (n=4) 
IV”c 1 (n=3) 
a 
1.87 
1.88 
1.71 
1.82 
2.01 
2.19 
P=O.O3 
2.16 
P=O.Ol 
1.84 
P=O.O5 
2.00 
NS 
2.61 
NS 
17 
14.9 
7.6 
9.9 
30 
10.67 10.05 6 
NS 
9.62 8.92 7.3 
P=O.O4 
9.34 8.48 9 
P= 0.004 
9.35 7.91 15 
NS 
8.34 7.13 15 
NS 
RV, residual volume (1); TXO, carbon monoxide diffusing capacity (mmol min - ’ kPa ~ I); 
NS, not significant. 
Row (a), significance of differences between first and last measurements, ‘%’ column 
showing percent change during study. 
in almost all groups during the study. The These RV changes could either be due to 
changes are most marked in tobacco smokers, narrowing of bronchioles with consequent air- 
but are also seen in ex- and non-smokers trapping, or damage to alveolar tissue with loss 
[Table 3(a)]. Similarly, an increased RV was of elastic recoil. There have been previous 
seen in CDC Groups II, PGL and ARC reports of the development of bullous disease 
[Table 3(b)]. When those subjects who demon- and emphysema in HIV-seropositive subjects. 
strated a clinical deterioration during the Thus, Kuhlman et al. (12) studied 55 patients 
study period were excluded, the increases in RV with AIDS (mean age 37 years) and found 
maintained their level of significance. There that 42% had ‘bullous changes’ on computed 
was no tendency for total lung capacity to tomographic (CT) scanning. This finding was 
change. less common in similarly immunocompromised 
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FIG. 1. Change in percent predicted carbon mon- 
oxide diffusing capacity (TECO) in smokers (0, n= 9) 
FIG. 2. Change in percent predicted residual volume 
in smokers (0, n = 9) and non-smokers (u, y1= 7) 
and non-smokers (E, n=7) who attended for 1 yr. who attended for 1 yr. Values at 3, 6, 9 and 12 
Values at 3; 6, 9 and 12 months are compared to months are compared to values at enrolment. 
values at enrolment. “PcO.05, “fPcO.01, jP<O.OOl. "P<O.O5, jP<O.OOl. 
patients with leukaemia. Bullae were not more 
common in smokers but most subjects with 
bullae had a history of pulmonary infection, 
particularly PCP. Diaz et al. (13) described four 
HIV-positive men (mean CD4= 100) who had 
evidence of emphysema-like lung disease. Three 
were smokers, all had elevations of RV and 
FRC, and reductions of FEV, which were 
generally mild; KC0 was very low. Three 
subjects had bullous disease on thin-slice CT. 
Thus, it would appear that a proportion of 
HIV-positive subjects are rapidly developing 
an emphysema-like lung disease. A possible 
mechanism for this was proposed by Buhl et al. 
(14), who demonstrated a deficiency of gluta- 
thione in lung epithelial lining liquid of 
HIV-positive subjects, and suggested that conse- 
quently its antioxidant activity is reduced. This 
could expose lung tissue to a risk of oxidant 
damage, particularly in the context of cigarette 
smoking. 
A reduction of TLC0 is well described in 
HIV-positive subjects with PCP, where TLC0 
falls acutely, and subsequently recovers partially 
over several months (4). The authors’ own find- 
ings confirm this in five subjects who had an 
episode of PCP during the study. Although they 
were excluded from the main analysis, they were 
80 ’ I 
0 3 
I I I 
6 9 12 15 
Months 
followed-up; only one of the five demonstrated 
a complete recovery within 5 months of PCP 
infection. 
This study has described gas transfer in terms 
of TACO. The transfer coefficient was also 
obtained, by dividing 2X20 by VA of each 
single-breath measurement. easurements of 
KC0 were seen to follow the changes in TACO. 
However, these changes in KC0 were less 
marked than those observed for YLCO due to 
the increased scatter which occurs when a ratio is 
taken between two variables. For this reason, the 
authors have concentrated on the TeCO data in 
their analysis. 
It has been suggested that TLC0 remains 
stable in HIV-positive subjects in the absence 
of clinical deterioration as determined by CDC 
grouping (4). By contrast, the present study 
shows significant deterioration in several lung 
function variables in subjects remaining clini- 
cally stable in the same CDC group [see Table 
3(b)]. The decrement in TLC0 was found to 
be highest in current smokers and lowest in life- 
time non-smokers: with intermediate values in 
ex-smokers. These differences were apparent in 
the initial data collected at recruitment, and 
were also seen at all subsequent times of 
measurement. 
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The present findings contrast with those of 
Nieman et al. (15) who found no statistically 
significant difference in TLC0 between smokers 
and non-smokers. This may be because their 
‘non-smoking’ group also included subjects who 
had given up smoking, whereas in the present 
study, the non-smoking group consisted only of 
life-time non-smokers. Inclusion of ex-smokers 
in this way may diminish the apparent difference 
between smokers and ‘non-smokers’. A study by 
Watson et al. (16) has cast light on the effect of 
current and past smoking on YUZO, irrespective 
of HIV infection. In a cohort of male subjects 
(mean age 42 years) with documented smoking 
habits over a lo-yr period, nC0 averaged 95, 
97 and 76% of predicted normal values in 
non-smokers, ex-smokers and current smokers, 
respectively. Values in smokers who stopped 
during the study increased, demonstrating that 
the effect of smoking on nC0 is reversible. The 
corresponding values in the present study show a 
similar effect of smoking on nC0 in subjects at 
enrolment (mean age 39 years), these being X8, 
88 and 77% predicted, respectively. Assuming 
that the subjects and measurements are compar- 
able in each of the study groups, the present data 
suggest that HIV infection per se reduces TLC0 
in non-smoking subjects. However, comparison 
and interpretation of the results in ex-smokers in 
both studies is difficult because scale of cigarette 
exposure and duration of abstinence cannot be 
directly compared and may be of importance. 
The present study also showed a fall of percent 
predicted ?XCO over a 12-month period of 
observation ( - 7.7% per annum in non-smokers; 
- 12% in smokers). By contrast, non-smokers 
and ex-smokers in the study quoted above (16) 
showed no fall in % predicted TLC0 after 10 yr, 
whilst smokers showed a fall of only 05% per 
annum. Others have also observed extremely 
rapid rates of TLC0 decline in HIV-positive 
individuals. Kvale et al. (3) found 60 out of a 
total of 1171 HIV-positive subjects who showed 
a >20% fall in TLC0 over 2 yr, unassociated 
with respiratory infection or symptoms. Rate of 
fall did not relate to CD4 counts; smoking was 
not examined. Many of this group were investi- 
gated with induced sputum examination, 
bronchoalveolar lavage and transbronchial lung 
biopsy, but no evidence of lung infection was 
found. In two subjects, transbronchial lung 
biopsy showed evidence of non-specific inter- 
stitial pneumonitis. Backer et al. (8) describe 
time-related changes in diffusing capacity in 51 
asymptomatic HIV patients. The transfer coeffi- 
cient was seen to fall 7% in a 9-month period, 
this decrease not being associated with any 
reduction in immune function (CD4) or spiro- 
metric measurements. Smoking status was not 
defined in this study. 
In conclusion, the present authors have shown 
that there is evidence of continuing lung damage 
in HIV-positive subjects who are clinically stable 
and have no overt lung disease. This damage is 
manifest by an increase in RV and a decline in 
TACO. The smoking group in this study, at 
enrolment, demonstrated a significantly lower 
value of nC0 when compared with life-long 
non-smoking HIV-positive subjects, and when 
compared with their predicted values. Carbon 
monoxide diffusing capacity was shown to 
decline at each subsequent 3-month interval over 
a period of 1 yr, and these differences between 
smoking and non-smoking subjects remained 
apparent. However, the rates of decline of TLC0 
over this period did not reveal any significant 
differences. 
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